Viridian Therapeutics, Inc. (VRDN)

In October 2025, Viridian completed financing transactions, securing up to $889 million and submitted its Biologics License Application (BLA) for veligrotug to the FDA. In November 2025, Viridian reported its third-quarter financial results, showing a revenue surge to $70.57 million. In December 2025, UBS Group upgraded Viridian Therapeutics' stock to a "strong-buy" rating, and William Blair reiterated a Buy rating. In January 2026, the FDA accepted Viridian's BLA for veligrotug under Priority Review, setting a target action date of June 30, 2026. As of January 8, 2026, the share price was $30.33, representing an increase of 66.65% from January 10, 2025.

Information specifically detailing demand seasonality for Viridian Therapeutics, Inc.'s products and services is not explicitly available. As a clinical-stage biopharmaceutical company, its current revenue is primarily driven by R&D spending and capital raises, rather than product sales. Demand for its products, once commercialized, would likely be influenced by the prevalence of Thyroid Eye Disease and other autoimmune conditions it targets, rather than traditional seasonal patterns.

Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and rare diseases, operating within the Healthcare sector and Biotechnology industry. The company's primary focus is on developing treatments for Thyroid Eye Disease (TED). Its major product candidates include Veligrotug, a humanized monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) for the treatment of active and chronic TED, VRDN-003, a next-generation IGF-1R monoclonal antibody engineered for subcutaneous administration for TED, and VRDN-006 and VRDN-008, a portfolio of engineered anti-neonatal Fc receptor (FcRn) inhibitors being developed for multiple autoimmune diseases.

Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. The company conducts global Phase 3 clinical trials for its lead candidates, indicating an international reach in its development activities.

Viridian Therapeutics' brand reputation appears positive, driven by clinical advancements and analyst sentiment. The company has a consensus rating of "Moderate Buy" from analysts, with a strong buy recommendation from UBS and William Blair. The successful BLA submission and FDA acceptance for Priority Review have reinforced investor optimism. Positive topline data from Phase 3 trials for veligrotug have also contributed to a favorable outlook. Potential risks that could affect reputation include the company's current unprofitability, a history of shareholder dilution, delayed launch of veligrotug, potential negative outcomes from the REVEAL studies for VRDN-003, intellectual property protection, manufacturing risks, and regulatory hurdles.

Viridian Therapeutics, Inc. has an ownership structure heavily concentrated in institutional investors. Approximately 97.66% of the company's stock is held by institutional shareholders, 32.59% by Viridian Therapeutics insiders, and 0.00% by retail investors according to one source, while another indicates 86.81% by institutional investors, 4.13% by insiders, and 9.06% by public companies and individual investors. Major institutional owners include Fmr LLC, BlackRock, Inc., and The Vanguard Group Inc. Logos Global Master Fund LP is noted as the largest individual Viridian Therapeutics shareholder, owning 6.00 million shares, representing 6.29% of the company.